https://www.selleckchem.com/products/nd-630.html
Therefore, HDAC9 may be a potential target for individualized treatment of patients with different histological subtypes of ovarian cancer.Adoptive cell therapy with NY-ESO-1-specific T cells is a promising option for the treatment of soft tissue sarcoma (STS) but achieves only transient tumor control in the majority of cases. A strategy to optimize this cell therapeutic approach might be the modulation of the expression of the cancer-testis antigen NY-ESO-1 using histone deacetylase inhibitors (HDACis). In this study, the ex vivo effect
Like
Comment
Share
